However, these inhibitors do not bind Mcl-1 with as high affinity, and their therapeutic potential is constrained by dose-limiting thrombocytopenia associated with potent Bcl-XL inhibition in platelets [29]. This evidence concerns the gene BCL2L1 and Thrombocytopenia.